Cotrimoxazole prophylactic treatment prevents malaria in children in sub‐Saharan Africa: systematic review and meta‐analysis. Issue 9 (8th July 2014)

• Record Type: Journal Article
• Authors: Mbeye, Nyanyiwe M.; ter Kuile, Feiko O.; Davies, Mary‐Ann; Phiri, Kamija S.; Egger, Matthias; Wandeler, Gilles; IeDEA‐Southern Africa
• Is Part Of: Tropical medicine & international health. Volume 19:Issue 9(2014:Sep.)
• Page Start: 1057
• Page End: 1067
• Publication Date: 2014-07-08
• Subjects: Tropical medicine -- Periodicals; Public health -- Periodicals; 616.988
• DOI: 10.1111/tmi.12352
• Languages: English
• ISSNs: 1360-2276

Abstract

<abstract abstract-type="main" id="tmi12352-abs-0001"> <title>Abstract</title> <sec id="tmi12352-sec-0001" sec-type="section"> <title>Objectives</title> <p>Cotrimoxazole prophylactic treatment (CPT) prevents opportunistic infections in HIV‐infected or HIV‐exposed children, but estimates of the effectiveness in preventing malaria vary. We reviewed studies that examined the effect of CPT on incidence of malaria in children in sub‐Saharan Africa.</p> </sec> <sec id="tmi12352-sec-0002" sec-type="section"> <title>Methods</title> <p>We searched PubMed and EMBASE for randomised controlled trials (RCTs) and cohort studies on the effect of CPT on incidence of malaria and mortality in children and extracted data on the prevalence of sulphadoxine‐pyrimethamine resistance–conferring point mutations. Incidence rate ratios (IRR) from individual studies were combined using random effects meta‐analysis; confounder‐adjusted estimates were used for cohort studies. The importance of resistance was examined in meta‐regression analyses.</p> </sec> <sec id="tmi12352-sec-0003" sec-type="section"> <title>Results</title> <p>Three RCTs and four cohort studies with 5039 children (1692 HIV‐exposed; 2800 HIV‐uninfected; 1486 HIV‐infected) were included. Children on CPT were less likely to develop clinical malaria episodes than those without prophylaxis (combined IRR 0.37, 95% confidence interval: 0.21–0.66), but there was substantial between‐study heterogeneity (<italic>I</italic>‐squared = 94%, <italic>P</italic> < 0.001). The protective efficacy of CPT was highest in an RCT from Mali, where the prevalence of antifolate resistant plasmodia was low. In meta‐regression analyses, there was some evidence that the efficacy of CPT declined with increasing levels of resistance. Mortality was reduced with CPT in an RCT from Zambia, but not in a cohort study from Côte d'Ivoire.</p> </sec> <sec id="tmi12352-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Cotrimoxazole prophylactic treatment reduces incidence of malaria and mortality in children in sub‐Saharan Africa, but study designs, settings and results were heterogeneous. CPT appears to be beneficial for HIV‐infected and HIV‐exposed as well as HIV‐uninfected children.</p> </sec> </abstract>